A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
- Study HIC#:2000036467
- Last Updated:03/26/2026
A phase ½ open label study of autologous CD19-Specific Chimeric Antigen Receptor T Cells (CABA-201) in active moderate to severe systemic lupus erythematous or lupus nephritis, sponsored by Cabaletta Bio, Inc.
This treatment consists of using patient’s own cells that are engineered to treat lupus by targeting the B cells that may be causing the disease. Participants will be given a single dose of CABA-201 in the hospital and followed in the outpatient setting.
Contact Us
For more information about this study, including how to volunteer, contact:
Yale Lupus Research Program
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
